Biotechnology News and Research

RSS

AHM completes acquisition of Advogent Group

Advanced Health Media, LLC (AHM), the leading U.S. provider of pharmaceutical sales, marketing and compliance technology and services, announced it has acquired substantially all of the assets of Advogent Group, Inc. (Advogent), a Piscataway, NJ-based provider of marketing services for the pharmaceutical industry.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Researchers identify 1.1M base pairs of DNA in soybean genome

In 2009, soybeans represented an almost $30 billion industry in the U.S. alone, making soybeans the second-most profitable crop next to corn. Worldwide, soybeans have been used in human foods and livestock feed for centuries and have been a key component in industrial products, such as plastics and soy biodiesel, an environmentally friendly fuel.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

BRAIN, Bayer Schering Pharma collaborate in production process optimisation of steroid compounds

BRAIN AG, an European leader in white biotechnology and the global top 10 pharmaceutical corporation Bayer Schering Pharma AG co-operate in the field of production process optimisation of steroid compounds. The goal of the collaboration is the energy-efficient and thus sustainable fermentative production of steroid compounds using optimised microbial production strains taking plant derived raw materials as starting material.

2 Feb 2010

First annual Translational Regenerative Medicine Forum to be held in Winston-Salem

The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

2 Feb 2010

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

EPO to grant patent notice to BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”.

2 Feb 2010

SDI selected for third consecutive time as key monoclonal antibody provider

SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative (CPTC: http://proteomics.cancer.gov).

2 Feb 2010

Danaher acquires Life Technologies' mass spectrometry business

Life Technologies Corporation, a provider of innovative life science solutions, has completed the previously announced sale of its mass spectrometry business to Danaher Corporation for $450 million in cash, subject to a conventional working capital adjustment.

From Danaher 2 Feb 2010

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

Phosphagenics Limited today announced positive results from a Phase 1B clinical study using the Company’s patented TPM™ (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The results of the successful trial demonstrate that daily application of a TPM™ patch delivers therapeutic levels of oxycodone into the blood stream in a reproducible, consistent and sustained manner.

2 Feb 2010

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

2 Feb 2010

Stem Cell Therapy International completes merger with Histostem of South Korea

Stem Cell Therapy International, Inc. announced that it has completed its merger with Histostem Ltd. of South Korea ("Histostem"), forming one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity.

2 Feb 2010

Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement

Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

From Fluxion Biosciences 2 Feb 2010

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

1 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease.

1 Feb 2010

ISO renewal audit for KIKA Clinical Solutions' U.S. and France operations complete

KIKA™ Clinical Solutions announced the successful completion of its ISO renewal audit for its operations in the U.S. and France. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

1 Feb 2010

Biotechnology News and Research

AHM completes acquisition of Advogent Group

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Researchers identify 1.1M base pairs of DNA in soybean genome

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

BRAIN, Bayer Schering Pharma collaborate in production process optimisation of steroid compounds

First annual Translational Regenerative Medicine Forum to be held in Winston-Salem

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

EPO to grant patent notice to BioMimetic Therapeutics

SDI selected for third consecutive time as key monoclonal antibody provider

Danaher acquires Life Technologies' mass spectrometry business

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

Stem Cell Therapy International completes merger with Histostem of South Korea

Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

Cephalon to acquire Swiss-based pharmaceutical company

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

ISO renewal audit for KIKA Clinical Solutions' U.S. and France operations complete

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News